Maksiller sinüsün Mantle hücreli lenfoması: olgu sunumu
Mantle hücreli lenfoma (MHL) çok sayıda B-hücreli lenfoma subtiplerinden biridir. Ekstra nodal tutulum sıktır, en sık kemik iliği, karaciğer, dalak, Waldeyer halkası ve gastrointestinal kanal tutulumu gözlenir. Tüm habis lenfomalarda olduğu gibi tanı için eksizyonel lenf düğümü biyopsisi tercih edilir. Erken evre MHL hastalarında 3-4 kür sistemik kemoterapi sonrası radyoterapi uygulaması uygun bir tedavi yaklaşımı olarak görülmektedir. Bizim olgumuzda elli yaşında bayan hastada 1 aydır geçmeyen diş ağrısı ile birlikte yüzde şişlik, asimetri, gözde öne itilme şikayetleri mevcuttu. Radyolojik değerlendirme sonrası maksiler sinüsten alınan biyopsi sonucu Mantle Hücreli Lenfoma olarak bildirildi. Sinonazal MHL’de nazal obstrüksiyon, epistaksis, yüzde şişlik, rinit, görme bozukluğu ve gözde çıkıklık gibi nonspesifik semptomlar görülebilir. Semptomların non spesifik seyrettiği bu hastaların ayırıcı tanısında lenfoma mutlaka düşünülmelidir.
Mantle cell lymphoma of the maxillary sinus: case report
Mantle cell lymphoma (MCL) is one of the many subtypes of B-cell lymphoma. Extra nodal involvement is common and most commonly observed in bone marrow, liver, spleen, Waldeyer ring and gastrointestinal tract. As in all malignant lymphomas excisional lymph node biopsy is preferred for diagnosis. In early stage of MCL, radiotherapy is considered to be a suitable treatment approach after 3-4 cycles of systemic chemotherapy. In our case, a fifty-year-old female patient had complaints of swelling and asymmetry on the face, propitosis with dental pain not exceeding 1 month. After radiologic evaluation, maxillary sinus biopsy was reported as Mantle cell lymphoma. In sinonasal MHL, nonspecific symptoms such as nasal obstruction, epistaxis, swelling on the face, rhinitis, visual impairment and proptosis can be seen. The lymphoma should be considered in the different diagnosis of these patients in which the symptoms are nonspecific.
___
- 1. Lichtman MA, Kipps TJ, Seligsohn U, Kaushansky K, Prchal JT, Editors. Pathology of malignant lymphomas. Williams Hematology. San Diego: McGraw Hill; 2010.
- 2. Fisher SG, Fisher RI. Theepidemiology of non-Hodgkin’s lymphoma. Oncogene 2004; 23: 6524-34.
- 3. Logsdon MD, Ha CS, Kavadi VS, Cabanillas F, Hess MA, Cox JD. Lymphoma of the nasal cavity and paranasal sinuses: improved outcome and altered prognostic factors with combined modality therapy. Cancer. 1997; 80: 477-88.
- 4. Bertoni F, Zucca E, Cotter FE. Molecularbasis of Mantle cell lymphoma. Br J Haematol. 2004; 124: 130-40
- 5. Cortelazzo S, Ponzoni M, Ferreri AJ, Dreyling M. Mantle cell lymphoma. Crit Rev Oncol Hematol 2012; 82: 78-101
- 6. Smith A, Howell D, Patmore R et al. İncidence of haematological malignancy by sub-type: report from the haematological malignancy research network. Br J Cancer 2011; 105: 1684-92
- 7. Moller MB, Pederson NT, Christensen BE. Mantle cell lymphoma: prognostic capaticity of The folliculer lymphoma international prognostic index. Br J Hematol 2006; 133: 43-56.
- 8. Cheah CY, George A, Gine E et al. Central nervous system involvement in mantle cell lymphoma: clinical features, prognostic factors and outcomes from the European Mantle cell lymphoma network. Ann Oncol 2013; 24: 2119-23.
- 9. Karaman E, Yilmaz M, Alimoglu Y, Edizer DT, Isildak H, Ozek H. Extranodal sinonasal natural killer / T-cell lymphoma presenting as chronic sinusitis and necrotic wound infection. J Craniofac Surg 2009; 20: 2095-96.
- 10. Sakamoto M, Miyairi Y, Ishizawa M. Optimal specimen site for diagnosis of nasal T/NK cell lymphoma and treatment including bone marrow transplantation. ORL J Otorhinolaryngol Relat Spec 2003; 65: 275-78.
- 11.Fernandez V, Salamero O, Espinet B et al. Genomic and gene expression profiling define sindolent forms of Mantle cell lymphoma. Cancer Res 2010; 70: 1408-18